- FDA Approves Ivosidenib Tablets for IDH1|Mutant ...🔍
- Ivosidenib Extends Survival in Patients with Cholangiocarcinoma ...🔍
- Ivosidenib 🔍
- Ivosidenib Wins European Approval for IDH1|mutated AML and ...🔍
- ivosidenib 🔍
- Annotation of FDA Label for ivosidenib and IDH1🔍
- Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid ...🔍
- CStone announced new drug approval of China's first IDH1 inhibitor ...🔍
Ivosidenib
FDA Approves Ivosidenib Tablets for IDH1-Mutant ...
The FDA has approved ivosidenib Tablets (Tibsovo) for the treatment of patients with IDH1-mutant cholangiocarcinoma, as detected by an FDA ...
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in ...
Ivosidenib demonstrates “impressive single-agent efficacy, with durable responses in these high-risk patients with relapsed or refractory AML,” said Dr DiNardo.
Ivosidenib | Leukemia and Lymphoma Society
Generic name Ivosidenib Brand name(s), other common name(s) Tibsovo® Drug type Isocitrate dehydrogenase-1 (IDH1) inhibitor How the drug is given By mouth ...
Ivosidenib Extends Survival in Patients with Cholangiocarcinoma ...
Final results from the phase 3 clinical trial ClarIDHy showed that ivosidenib (Tibsovo), a first-in-class oral inhibitor of isocitrate dehydrogenase 1 ...
Tibsovo | European Medicines Agency (EMA)
The active substance in Tibsovo, ivosidenib, works by blocking the action of mutated forms of IDH1. Mutated IDH1 produces high levels of a substance called D-2- ...
Ivosidenib (CAS 1448347-49-6) - R&D Systems
View and buy high purity Ivosidenib. Potent inhibitor of mutant isocitrate dehydrogenase (mIDH1).
Ivosidenib Wins European Approval for IDH1-mutated AML and ...
The European Commission has approved ivosidenib tablets in combination with azacitidine for the treatment of adult patients with newly ...
ivosidenib (Tibsovo) - Scottish Medicines Consortium
Indication under review: as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an ...
Annotation of FDA Label for ivosidenib and IDH1 - PharmGKB
Summary. The FDA-approved drug label for ivosidenib (TIBSOVO) states that it is indicated for the treatment of acute myeloid leukemia (AML) with a susceptible ...
Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid ...
Olutasidenib and ivosidenib are inhibitors that target mutant IDH1 (mIDH1) and are FDA approved for the treatment of patients with mIDH1 AML.
CStone announced new drug approval of China's first IDH1 inhibitor ...
China has approved the new drug application (NDA) of TIBSOVO® (ivosidenib tablets) for the treatment of adult patients with relapsed/refractory acute myeloid ...
Ivosidenib and azacitidine | Cancer Research UK
Ivosidenib is a type of targeted cancer drug called a cancer growth blocker. It works by targeting certain proteins made by the changed IDH1 ...
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 ...
We report the discovery of AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to ...
Ivosidenib and Azacitidine Combination Shows Significant Clinical
Ivosidenib and azacitidine significantly improved event-free survival (EFS), response, and overall survival (OS) as compared with placebo and azacitidine.
Tibsovo (Ivosidenib) First Targeted Therapy Approved for Patients ...
The FDA approved ivosidenib (Tibsovo; Agios Pharmaceuticals), an oral targeted therapy that inhibits IDH1, for the treatment of adults with relapsed or ...
Ivosidenib Monotherapy May Be Effective in IDH1-Mutant MDS
Researchers determined ivosidenib monotherapy may be effective in treating a subset of patients with IDH1-mutated MDS.
FDA approves the frontline use of ivosidenib in AML patients ... - BJH
FDA approves the frontline use of ivosidenib in AML patients with IDH1 mutation ... The Food and Drug Administration (FDA) has approved the use of ivosidenib ( ...
Use, access, and initial outcomes of off-label ivosidenib in patients ...
Ivosidenib (IVO), a small molecule oral mIDH1 inhibitor, is FDA-approved for mIDH1 newly diagnosed and relapsed/refractory acute myeloid leukemia.
If your doctor recommended the administration of ivosidenib to treat your cancer, here is some important information about this medication and some aspects ...
Ivosidenib: uses, dosing, warnings, adverse events, interactions
Relapsed or Refractory Acute Myeloid Leukemia. Ivosidenib is used for the treatment of adults with relapsed or refractory AML with asusceptible IDH1 mutation.